An interventional study of Health kiosk in Opioid-Related Disorders, Hepatitis C (HCV) and Human Immunodeficiency Virus (HIV), sponsored by April M Young. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-18.
Sponsored by April M Young · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,223 studies in Opioid-Related Disorders with a site in United States — 246 open to participants now, 316 under way, 18 of them phase 3. Opioid-Related Disorders · United States.
Among the 1,223 studies in Opioid-Related Disorders with a site in United States, this one is the 58th largest by enrollment of the 1,098 interventional ones that give a count, is one of 84 that started in 2023, is one of 571 with no phase, reaches primary completion later than 144 of the 315 other live ones, and was the 887th registered.
1,475 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.
Browse Opioid-Related Disorders studies →246 of the 1,223 studies in Opioid-Related Disorders with a site in United States are open now. Recruiting first, the newest first:
Washington State University · Sites in United States
Ages 18+
University of Massachusetts, Worcester · Sites in United States
Ages 18+ · Healthy volunteers
Ohio State University · Sites in United States
Ages 21–65
University of Kentucky · Sites in United States
Ages 18–75
Baylor College of Medicine · Sites in United States
Ages 18–64
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,223 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 162 · Phase 2 245 · Phase 3 99 · Phase 4 79
First in 1988; this study’s year is marked. 84 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 752 is above the median of 63 across 1,170 interventional studies indexed under Opioid-Related Disorders.
Median enrollment 56 across the 1,098 interventional studies, 85 across the 122 observational. Of the 834 that completed or were terminated, 332 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
132 of 1,223 have an industry lead sponsor. The 10 most frequent:
April M Young is the lead sponsor of 2 studies on the registry; none are open to participants now.
April M Young has 1 study filed under Opioid-Related Disorders — fewer than ten, so there is no comparison to draw.
129 of the studies in Opioid-Related Disorders with a site in United States that are under way reach primary completion within a year, 9 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05011266Phase 3New York State Psychiatric InstituteEfficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder | 2027-01-01 |
| NCT05834478Phase 3Emory UniversityNon-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3 | 2027-02 |
| NCT05033028Phase 3NYU Langone HealthSmartphones for Opiate Addiction Recovery | 2027-06-01 |
| NCT05459402Phase 3University of Maryland, BaltimoreDivided or Single Exposure (DOSE) Study | 2027-06-01 |
| NCT05766631Phase 3Friends Research Institute, Inc.Treating Polysubstance Use Using a Novel Digital Technology | 2027-06-30 |
Add all 129 to your calendar (.ics) → With an account.
Among the 1,223 studies in Opioid-Related Disorders with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will test the effectiveness, implementation outcomes, and cost effectiveness of a locally-tailored, health kiosk to reduce overdose, hepatitis C, and HIV risk behavior and improve linkage to care in rural Appalachia. The proposed project will take place in two counties in Appalachian Kentucky, an epicenter for the intertwined national crises of overdoses, hepatitis C, and injection-related infections.
This is a Type 1 hybrid effectiveness study involving a community-level, controlled quasi-experimental trial to assess the impact of a community-tailored health kiosk on HIV, HCV, and overdose risk in rural Appalachia, and a mixed methods evaluation of implementation outcomes. The trial will compare the standard health department program (staffed, brick-and-mortar) to an enhanced model involving a health kiosk + standard health department program. The kiosk, referred to as the KyOSK (Kentucky Outreach Service Kiosk) will be tailored through a community-engaged adaptation process. For evaluation of the KyOSK, the investigators will enroll 750 People Who Use Drugs (PWUD) in the intervention (n=425) and comparison (n=325) counties, collectively referred to as the kiosk trial cohort. The kiosk trial cohort will be recruited from three sources: existing cohorts of PWUD, local agencies, and peer-referral. Throughout the trial and following the implementation outcome framework (IOF) measurement model by Proctor et al., acceptability, appropriateness, fidelity, cost, penetration, and sustainability will be assessed using a combination of validated scales, qualitative interviews, checklists, invoices, and program data. Following the trial, the investigators will use data collected from the kiosk cohort and implementation outcome assessment (primarily cost and reach) in a dynamic, deterministic model of HCV transmission and overdose to examine the impact and cost-effectiveness of the KyOSK model.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Individuals are eligible if they are:
Exclusion Criteria:
Individuals are not eligible if they meet any of the exclusion criteria:
The intervention involves enhancing the health department's existing staffed model of service delivery with a KyOSK. The intervention county's staffed program operates identically to the comparison county. Both counties' staffed programs and the kiosk will use an identically structured unique ID to provide objective data on service engagement. The KyOSK will resemble a vending machine but with a touchscreen, audiovisual interface. The KyOSK will include naloxone, wound care kits, and supplies for basic needs (e.g., hygiene items, food, water, emergency blankets); offer overdose education materials; and an innovative call-back feature for care navigation by recovery coaches. While the KyOSK is operating, the county will continue to operate its traditional program.
Behavioral: Health kiosk
A staffed program located in the local department of health (DOH) and staffed by DOH personnel currently operates in the comparison county. The program provides supplies (e.g., naloxone, wound care kits, snacks, drinks, resource guides). A peer support specialist from a nearby recovery facility is present for consultation with clients (by request of client) during operating hours. New clients to the program "register" by providing information for establishment of a client ID and answer a brief survey of demographic and behavioral questions used by all state programs. Program clients will also receive a resource guide covering the same categories as those covered in the call-back feature of the KyOSK.
The intervention involves enhancing its existing health department model with a Kentucky Outreach Service Kiosk (KyOSK).
Change in number of days carrying naloxone
Self-reported recent (past 30-day) frequency of carrying naloxone (continuous)
Time frame: Measured at baseline and then every 6 months up to 5 years
Change in frequency of use of substance use treatment, detoxification, and/or peer-support services
Self-reported recent (past 6-month) frequency of engaging in substance use treatment services (binary)
Time frame: Measured at baseline and then every 6 months up to 5 years
Change in number of injection-related abscesses
Self-reported recent (past 6 month) number of injection-site abscesses among those who inject drugs (continuous)
Time frame: Measured at baseline and then every 6 months up to 5 years
Change in frequency of condom-less anal and/or vaginal sex
Self-reported recent (past 30-day) frequency of anal or vaginal sex without a condom (continuous; number and proportion of all sex events)
Time frame: Measured at baseline and then every 6 months up to 5 years
Change in frequency of overdose
Self-reported number of times overdosed in the past 6 months (continuous).
Time frame: Measured at baseline and then every 6 months up to 5 years
Change in use of naloxone during overdose events by participants who witnessed an overdose
Self-reported number of times participant used naloxone to reverse someone's overdose in the past 6 months (continuous)
Time frame: Measured at baseline and then every 6 months up to 5 years
Change in number of days on medications for opioid use disorder (MOUD) among participants who use opioids to get high
Self-reported recent (past 30-day) frequency of being on MOUD (continuous)
Time frame: Measured at baseline and then every 6 months up to 5 years
Change in frequency of helping others access naloxone
Self-reported recent (past 6 months) frequency of providing naloxone to others (binary)
Time frame: Measured at 18-month follow-up and thereafter
Change in frequency of hospitalization for an injection-related infection
Self-reported recent (past 6 month) hospitalization for an injection-site infection among those who inject drugs (binary)
Time frame: Measured at baseline and then every 6 months up to 5 years
Change in frequency of helping others access wound care
Self-reported recent (past 6 month) frequency of providing wound care supplies to other (binary)
Time frame: Measured at 18-month follow-up and thereafter
Change in recovery capital
Composite measure of recent (past 6 month) self-reported social capital (receipt and provision of support), physical capital (housing, transportation, food security, technology, and health care access), and human capital (quality of life, experience of shame) (continuous)
Time frame: Measured at baseline and then every 6 months up to 5 years
Plan to share: No
Started Mar 2023 (actual). Primary completion is estimated for May 2027, 50 months after the start.
Of 465 non-industry interventional studies with no phase under Opioid-Related Disorders, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 47. This study's planned 50 months is above that.
Counting every sponsor, half of 496 studies reached it within 29 months; a quarter within 13 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
April M Young